Bristol-Myers Squibb (BMS) has denied allegations by the Treatment Action Campaign (TAC) that the U$100-million HIV/Aids grant made by the pharmaceutical giant last year to five southern African countries, including South Africa, was an attempt to "silence the voice of affordable medicine".